Serum levels of soluble CD95 are not associated with amelioration of multiple sclerosis during pregnancy

Journal of the Neurological Sciences

Volumn 252, Issue 1, 2007, Pages 83-87

  Ehrlich, Stefan ^a   Haas, Judith ^b   Zipp, Frauke ^a   Infante Duarte, Carmen ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Jewish Hospital Berlin   (Germany)

Author keywords

Autoimmunity; Multiple Sclerosis; Pregnancy; Sex steroid hormones; Soluble CD95; T cell apoptosis

Indexed keywords

FAS ANTIGEN;

ANALYTIC METHOD; APOPTOSIS; ARTICLE; AUTOIMMUNITY; BLOOD LEVEL; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DISEASE ASSOCIATION; EFFECTOR CELL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; PREGNANCY; PRIORITY JOURNAL; RECURRENT DISEASE; T LYMPHOCYTE;

ANALYSIS OF VARIANCE; ANTIGENS, CD95; ENZYME-LINKED IMMUNOSORBENT ASSAY; FAS LIGAND PROTEIN; FEMALE; HUMANS; MULTIPLE SCLEROSIS; PREGNANCY; T-LYMPHOCYTES;

EID: 33845528763     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2006.10.013     Document Type: Article

References (25)

1. Sospedra M., and Martin R. Immunology of multiple sclerosis. Annu Rev Immunol 23 (2005) 683-747
2. Confavreux C., Hutchinson M., Hours M.M., Cortinovis-Tourniaire P., and Moreau T. Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group. N Engl J Med 339 (1998) 285-291
3. Vukusic S., Hutchinson M., Hours M., Moreau T., Cortinovis-Tourniaire P., Adeleine P., et al. Pregnancy and multiple sclerosis (the PRIMS study): clinical predictors of post-partum relapse. Brain 127 (2004) 1353-1360
4. van Walderveen M.A., Tas M.W., Barkhof F., Polman C.H., Frequin S.T., Hommes O.R., et al. Magnetic resonance evaluation of disease activity during pregnancy in multiple sclerosis. Neurology 44 (1994) 327-329
5. Keith A.B. Effect of pregnancy on experimental allergic encephalomyelitis in guinea pigs and rats. J Neurol Sci 38 (1978) 317-326
6. Crawford M.P., Yan S.X., Ortega S.B., Mehta R.S., Hewitt R.E., Price D.A., et al. High prevalence of autoreactive, neuroantigen-specific CD8+ T cells in multiple sclerosis revealed by novel flow cytometric assay. Blood 103 (2004) 4222-4231
7. Zipp F., Krammer P.H., and Weller M. Immune (dys)regulation in multiple sclerosis: role of the CD95-CD95 ligand system. Immunol Today 20 (1999) 550-554 [00001545]
8. Nagata S., and Suda T. Fas and Fas ligand: lpr and gld mutations. Immunol Today 16 (1995) 39-43
9. Nagata S. Human autoimmune lymphoproliferative syndrome, a defect in the apoptosis-inducing Fas receptor: a lesson from the mouse model. J Hum Genet 43 (1998) 2-8
10. Papoff G., Cascino I., Eramo A., Starace G., Lynch D.H., and Ruberti G. An N-terminal domain shared by Fas/Apo-1 (CD95) soluble variants prevents cell death in vitro. J Immunol 156 (1996) 4622-4630
11. Cheng J., Zhou T., Liu C., Shapiro J.P., Brauer M.J., Kiefer M.C., et al. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 263 (1994) 1759-1762
12. Zipp F., Weller M., Calabresi P.A., Frank J.A., Bash C.N., Dichgans J., et al. Increased serum levels of soluble CD95 (APO-1/Fas) in relapsing-remitting multiple sclerosis. Ann Neurol 43 (1998) 116-120
13. Zipp F., Otzelberger K., Dichgans J., Martin R., and Weller M. Serum CD95 of relapsing remitting multiple sclerosis patients protects from CD95-mediated apoptosis. J Neuroimmunol 86 (1998) 151-154
14. Poser C.M., Paty D.W., Scheinberg L., McDonald W.I., Davis F.A., Ebers G.C., et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 13 (1983) 227-231
15. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33 (1983) 1444-1452
16. Singer J.D., and Willett J.B. Applied longitudinal data analysis: modeling change and event occurrence (2003), Oxford Press, New York
17. Vukusic S., and Confavreux C. Pregnancy and multiple sclerosis: the children of PRIMS. Clin Neurol Neurosurg 108 (2006) 266-270
18. Wegmann T.G., Lin H., Guilbert L., and Mosmann T.R. Bidirectional cytokine interactions in the maternal-fetal relationship: is successful pregnancy a TH2 phenomenon?. Immunol Today 14 (1993) 353-356
19. Correale J., Arias M., and Gilmore W. Steroid hormone regulation of cytokine secretion by proteolipid protein-specific CD4+ T cell clones isolated from multiple sclerosis patients and normal control subjects. J Immunol 161 (1998) 3365-3374
20. Gilmore W., Arias M., Stroud N., Stek A., McCarthy K.A., and Correale J. Preliminary studies of cytokine secretion patterns associated with pregnancy in MS patients. J Neurol Sci 224 (2004) 69-76
21. Zenclussen A.C. CD4(+)CD25+ T regulatory cells in murine pregnancy. J Reprod Immunol 65 (2005) 101-110
22. Dimayuga F.O., Reed J.L., Carnero G.A., Wang C., Dimayuga E.R., Dimayuga V.M., et al. Estrogen and brain inflammation: effects on microglial expression of MHC, costimulatory molecules and cytokines. J Neuroimmunol 161 (2005) 123-136
23. Bruce-Keller A.J., Keeling J.L., Keller J.N., Huang F.F., Camondola S., and Mattson M.P. Antiinflammatory effects of estrogen on microglial activation. Endocrinology 141 (2000) 3646-3656
24. Jung-Testas I., Do Thi A., Koenig H., Desarnaud F., Shazand K., Schumacher M., et al. Progesterone as a neurosteroid: synthesis and actions in rat glial cells. J Steroid Biochem Mol Biol 69 (1999) 97-107
25. Sicotte N.L., Liva S.M., Klutch R., Pfeiffer P., Bouvier S., Odesa S., et al. Treatment of multiple sclerosis with the pregnancy hormone estriol. Ann Neurol 52 (2002) 421-428